Packaging fulfills the diverse role from protecting products, preventing spoilage, contamination, extending shelf life, ensuring safe storage thereby helping to make them readily available to consumers. India is one of the largest producers of commodities like food grains, sugar, milk, fruits, vegetables, pulses, tea and many other commodities. Plastics have emerged as the most preferred choice of packaging material for various products - from food, beverages, chemicals, electronic items and so on.

The report begins with the introduction section which offers a brief insight into the types of packaging done in India by way of function, way of packaging and type of packaging material used followed by the introduction into plastic packaging and the various types of plastics used for packaging. The market overview section provides an insight into the Indian packaging market and then moves on to the plastic packaging market, highlighting the market size and growth. Market segmentation of overall packaging market is also shown.

An analysis of the drivers explains the factors for growth of the plastic packaging industry. Demand for plastic packaging is expected to increase with the growth of retail sector and rising consumerism. Growing packaged food and beverage sector generates huge demand for plastic packaging segment. Demand from the FMCG and Pharmaceutical sector plays a key role in the growth of the market. Application of plastic packaging in paint and lubricant industry will add to the increasing use of plastic packaging. Under penetrated market provides significant opportunity for further growth. Changing lifestyle influencing the consumption pattern has positive impact on the plastic packaging segment. Contribution of rural sector coupled with logistics advantage will lead to strong growth in the market.

Companies Mentioned:

List of Public Companies

- BASF India Ltd.

- Essel Propack Ltd.

- Ester Industries Ltd.

- Jindal Poly Films Ltd.

- Manjushree Technopack Ltd.

- MoldTek Packaging Ltd.

- Nilkamal Ltd.

- Uflex Ltd.

List of Private Companies

- APT Packaging Ltd.

- Clear Mipak Packaging Solutions Ltd.

- Graham Blow Pack Private Ltd.

- Hidkari Industries Ltd.

- Parksons Packaging Ltd.

For more information visit http://www.researchandmarkets.com/research/q2drkb/plastic_packaging

“2012 U.S. Pharmacies & Drug Stores Industry-Industry & Market Report”

The Pharmacies & Drug Stores Industry-Industry & Market report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2012 current and 2013 forecast estimates on the size of the industry (sales, establishments, employment) nationally and for all 50 U.S. States and over 900 metro areas. New to the report this year are: financial ratios, number of firms and payroll estimates. The report also includes industry definition, 5-year historical trends on industry sales, establishments and employment, a breakdown of establishments, sales and employment by employee size of establishment (9 categories), and estimates on up to 10 sub-industries, including pharmacies and proprietary stores.

Please note, this report offers statistical information only and does not include an analysis of the figures

Key Topics Covered:

Users' Guide

Industry Definition and Related Industries

Industry Establishments, Sales & Employment Trends

Industry Ratios

Establishments, Firms & Payroll

Sub-Industries - 2011 Estimated Industry Sales ($Millions)

Sub-Industries - 2011 Estimated Number of Establishments

Sub-Industries - 2011 Estimated Number of Employees

5-Year Trend - Estimated Industry Sales ($Millions)

5-Year Trend - Estimated Number of Establishments

5-Year Trend - Estimated Number of Employees

2012 U.S. States - Estimated Number of Establishments

2012 U.S. States - Estimated Industry Sales ($Millions)

2012 U.S. States - Estimated Number of Employees

2013 U.S. States - Estimated Number of Establishments

2013 U.S. States - Estimated Industry Sales ($Millions)

2013 U.S. States - Estimated Number of Employees

2012 U.S. Metropolitan Areas - Estimated Number of Establishments

2012 U.S. Metropolitan Areas - Estimated Industry Sales ($Millions)

2012 U.S. Metropolitan Areas - Estimated Number of Employees

2013 U.S. Metropolitan Areas - Estimated Number of Establishments

2013 U.S. Metropolitan Areas - Estimated Industry Sales ($Millions)

2013 U.S. Metropolitan Areas - Estimated Number of Employees

Definitions and Terms

For more information visit http://www.researchandmarkets.com/research/8f5kft/2012_u_s_pharmaci

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (“RI”) STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other executive options)

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

(b) Derivatives transactions (other than options)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

(ii) Exercising

(d) Other dealings (including subscribing for new securities)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

(c) Attachments

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

143221.01

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. OPTIONS AND DERIVATIVES

3. AGREEMENTS TO PURCHASE OR SELL ETC.

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences (“CFDs”) or spread bets.

The currency of all prices and other monetary amounts should be stated.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (“RI”) STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other executive options)

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

(b) Derivatives transactions (other than options)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

(ii) Exercising

(d) Other dealings (including subscribing for new securities)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

(c) Attachments

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY (“RI”) STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other executive options)

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

(b) Derivatives transactions (other than options)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

(ii) Exercising

(d) Other dealings (including subscribing for new securities)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

(c) Attachments

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

(b) Derivatives transactions (other than options)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

(ii) Exercising

(d) Other dealings (including subscribing for new securities)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

“Demand in Emerging Markets in the Airport Industry - 2012-2013: Survey Snapshot”

This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading airport industry executives. It analyzes how demand expectations are set to change in the airport industry in 2012-13. The report also provides access to information categorized by company type, company turnover, buyer, supplier and region.

Scope

- The opinions and forward looking statements of 201 industry executives have been captured in our in-depth survey, of which 40% represent Director and C-level respondents.

- The research is based on primary survey research conducted by ICD Research accessing its B2B panels comprised of senior purchase decision makers and leading supplier organizations.

- The geographical scope of the research is global - drawing on the activity and expectations of leading industry players across the Americas, Europe, Asia-Pacific, Africa and Middle East.

- This report covers data and analysis on demand in emerging markets of global airport industry.

Reasons To Buy

This report will help you to...

- drive revenues by understanding market growth.

- uncover the business outlook and demand in emerging markets that are identified by suppliers and buyers.

Topics Covered

1 Introduction

1.1 What is this Report About?

1.2 Definitions

1.3 Methodology

1.4 Global Airports Industry: Profile of Survey Respondents

1.4.1 Global airports industry: profile of buyer respondents

1.4.2 Global airports industry: profile of supplier respondents

2 Global Airports Industry: Demand in Emerging Markets

2.1 Global airports industry: demand in emerging markets by buyers

2.2 Global airports industry: demand in emerging markets by suppliers

2.3 Global airports industry: demand in emerging markets by region

2.4 Global airports industry: demand in emerging markets by company turnover

3 Appendix

3.1 Full Survey Results - Closed Questions

3.2 Methodology

3.3 Contact us

3.4 About ICD Research

3.5 Disclaimer

For more information visit http://www.researchandmarkets.com/research/pft7wd/demand_in_emerging

Source: iCD Research

GWI’s traffic in July 2012 was 80,858 carloads, a decrease of 4,341 carloads, or 5.1 percent, compared with July 2011.

The table below sets forth consolidated carloading information for July 2012 and July 2011. Additional carload information for GWI’s North American and Australian operations is included as an exhibit to this press release.

Excluding 2,893 carloads from GWI railroads acquired within the last 12 months, same-railroad traffic in July 2012 decreased 7,234 carloads, or 8.5 percent, compared with July 2011. GWI’s other commodity group traffic decreased 4,568 carloads primarily due to no overhead coal shipments in GWI’s Ohio Region in July 2012. Minerals & stone traffic decreased 2,324 carloads primarily due to reduced rock salt shipments in GWI’s New York/Pennsylvania Region as a result of warm winter weather. Farm & food products traffic decreased 2,123 carloads primarily due to reduced shipments in GWI’s Australia and Illinois Regions. The shipment decline in the Australia Region was primarily due to an accelerated shipping schedule earlier in 2012. The shipment decline in the Illinois Region was primarily due to elevated traffic in 2011 associated with carloads diverted around flooding in the Midwest. Metals traffic decreased 1,178 carloads primarily due to reduced shipments in GWI’s Southern Region, where an expected maintenance outage affected shipment volumes in the month. All remaining traffic increased by a net 2,959 carloads.

Carload Reporting for Metallic Ores Traffic

Effective January 1, 2012, a portion of GWI’s metallic ores commodity group includes intermodal containers as a result of a change in rail logistics and equipment for a customer in GWI’s Australia Region. The impact of this change increased traffic by 538 carloads in July 2012.

Historically, GWI has found that carload information may be indicative of freight revenues on its railroads, but may not be indicative of total revenues, operating expenses, operating income or net income. Car movements related to railcar switching, including activities at port terminals, are excluded from our carload information as the resulting revenues are classified as non-freight.

GWI owns and operates short line and regional freight railroads and provides railcar switching services in the United States, Australia, Canada, the Netherlands and Belgium. In addition, we operate the Tarcoola to Darwin rail line, which links the Port of Darwin to the Australian interstate rail network in South Australia. Operations currently include 66 railroads organized in 10 regions, with more than 7,600 miles of owned and leased track and approximately 1,400 additional miles under track access arrangements. We provide rail service at 17 ports in North America and Europe and perform contract coal loading and railcar switching for industrial customers.

Exhibit

The table below sets forth North American carloading information for July 2012 and July 2011:

The table below sets forth Australian carloading information for July 2012 and July 2011:

“Allegro demonstrated the ability to meet these needs – within a challenging time line – with their agile approach to implementation which offers phased deployment of the software.”

As Australia’s leading renewable energy business, Hydro Tasmania utilises water and accesses wind power to generate renewable energy. It trades electricity and environmental products, including Renewable Energy Certificates (RECs) in the Australian market. Hydro Tasmania operates 30 hydropower stations, 50 major dams, and two diesel power stations. It also has equity interests in two wind farms with a third under development. In 2008, the company became a vertically integrated energy business with the acquisition of energy retailer Momentum Energy.

“Largely driven by our expansion into the mainland retail energy market, we needed a scalable software solution to support enterprise-wide activities, from deal capture to settlement. These include wholesale and retail pricing, position reporting, and tools to manage risk,” said Lance Balcombe, Hydro Tasmania’s Chief Finance Officer. “Allegro demonstrated the ability to meet these needs – within a challenging time line – with their agile approach to implementation which offers phased deployment of the software.”

To meet the challenges of Hydro Tasmania’s growing portfolio, Allegro 8 will provide the following business benefits:

• Mitigation of market and price risk with the ability to calculate intraday risk metrics and perform simulation across multiple portfolios. This includes the ability to easily capture and value options, swaps, swaptions and other hedge products
• Enhanced compliance monitoring
• Reduced counterparty credit risk with reporting and visibility into credit requests, ratings, limit monitoring, and availability
• Enhanced settlement processes with automated procedures to calculate prices, fees, and terms, and generate invoices, statements and accruals
• Improved staff efficiency with the elimination of manual processes and the ability to capture and confirm all deal types and attributes, including environmental commodities
• Improved timeliness, accuracy and availability of business data by replacing disparate systems with automated workflows and seamless integration with market data providers

About Allegro

Allegro is a global leader in energy trading & risk management solutions for power and gas utilities, refiners, producers, traders, and commodity consumers. With more than 28 years of deep industry expertise, Allegro’s enterprise platform drives profitability and efficiency across front, middle, and back offices, while managing the complex logistics associated with physical commodities. Allegro provides customers with agile solutions to manage risk across natural gas, power, coal, crude oil, petroleum products, emissions, and other commodity markets. Headquartered in Dallas, Texas, Allegro has offices in Calgary, Houston, London, Singapore, Sydney and Zurich, along with a global network of partners. www.allegrodev.com

“Polymer Industry in India - Export Opportunities and Promising Growth in Domestic Packaging and Automotive Sectors to Drive the Demand”

India's Rise to Polymers Powerhouse

An insatiable manufacturing industry, a surging economy, and supportive government policies have already made India a polymers superpower, but the best is yet to come, states a new report by business analysts The authors.

According to the report*, India is currently the world's third largest consumer of polymers, behind China and the US, with a share of 5.7% of the 2011 global total - an increase from it's 2000 portion size of 3.5%.

Growth in the polymers industry really kicked off in India after the country's economic liberalisation in 1991. The resulting deregulation and privatization sparked a boom in end-use sectors such as packaging, construction and automotive that has seen per capita consumption increase from 1kg in 1980 to 7.4kg in 2010.

This level, however, is still much lower than the world average and with surging industrialization and an increasingly powerful economy, the subcontinent still has massive as-yet largely untapped potential.

Production levels are soaring in order to keep up with India's ravenous demand. In 2011, the manufacture of polymer products was 7.377 Million Metric ton per annum (MMtpa), and this will surge at a CAGR of 9.4% to reach 11.575 MMtpa by just 2016.

The authors's research indicates that polymer demand in India is even outstripping the country's strong GDP growth; in the period 2000 to 2011, India's GDP climbed at a Compound Annual Growth Rate (CAGR) of 7.6%, whereas polymer consumption across all areas grew at a CAGR of 9.1%.

India's government has played a key role in boosting the significance of polymers, in terms of both consumer demand and in the production industry.

Publication Overview

This report provides an in-depth analysis of the Indian polymer industry. It highlights the major features of the industry and explains the reasons behind its impressive growth in the last decade.

Scope

- India's historic and forecast per capita plastics consumption

- Historical and forecast polymers capacity in India

- Polymer demand and production by commodity in India

- Global polymer demand and production share by region

- Global polymer capacity split by region

- Historic and forecast polymer imports into India

- Demand for polymers by the packaging and automotive sectors in India

- Historic processed plastics exports from India

- Forecast demand for polymers from the plasticulture sector in India

Reasons to Buy

- Understand end-use sectors which drive polymer demand in India.

- Develop business strategies with the help of specific insights on the polymers supply scenario in India.

- Identify opportunities in the Indian polymer industry with the help of specific insight on the polymer demand scenario in India.

- Increase future revenue and profitability with the help of insights into the future opportunities and critical success factors in the Indian polymer industry.

For more information visit http://www.researchandmarkets.com/research/sdgnnw/polymer_industry_i

Source: GlobalData

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

(b) Derivatives transactions (other than options)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

(ii) Exercising

(d) Other dealings (including subscribing for new securities)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

(b) Derivatives transactions (other than options)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

(ii) Exercising

(d) Other dealings (including subscribing for new securities)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

“Acetic Anhydride Industry Outlook in Japan to 2016 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants”

GlobalData's report, Acetic Anhydride Industry Outlook in Japan to 2016 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants provides an in-depth coverage of Japan Acetic Anhydride industry. The research presents major market trends affecting the Acetic Anhydride industry in Japan. The report covers Japan Acetic Anhydride plants and presents installed capacity by key feedstock, process and technology. In addition, it presents Acetic Anhydride demand and production forecasts, end use demand forecasts, price trends, trade balance data and company shares of the major Acetic Anhydride producers in Japan. Overall, the report presents a comprehensive coverage of Japan Acetic Anhydride industry including all the major parameters.

Scope

- Acetic Anhydride industry supply scenario in Japan from 2000 to 2016 consisting of plants capacity growth, installed plant capacity by key feedstock, production process and technology

- Information of all active and planned Acetic Anhydride plants in Japan with capacity forecasts to 2016

- Detailed information on all operating and planned projects covering details such as process, technology, key feedstock and operator and equity details

- Acetic Anhydride industry market dynamics in Japan from 2000 to 2016 consisting of market size, demand and production outlook, demand by end use sector, and average prices

- Trade balance data from 2000 to 2016 including import and export data, net exports and imports as percentage of demand in the country

- Company snapshots including company overview, business description and information on the current and upcoming Acetic Anhydride plants

- Company shares of key Acetic Anhydride producers in the country

Reasons to Buy

- Identify the macro and micro-economic trends affecting the Acetic Anhydride industry in Japan

- Understand the market positioning of Acetic Anhydride producers in Japan

- Develop market-entry and market expansion strategies

- Benchmark your operations and strategies against the major companies in Japan

For more information visit http://www.researchandmarkets.com/research/s39lgt/acetic_anhydride_i

Source: GlobalData

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

J.P. Morgan, BofA Merrill Lynch and Morgan Stanley will act as the joint book-running managers for the proposed IPO. When available, copies of the preliminary prospectus relating to the proposed IPO may be obtained from J.P. Morgan, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or telephone: 1-866-803-9204; BofA Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or email: dg.prospectus_requests@baml.com; or Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or telephone: 1-866-718-1649, or email: prospectus@morganstanley.com.

About Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

About Pfizer Animal Health

Pfizer Animal Health, a business unit of Pfizer Inc., is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. For more than 60 years, we have been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them.

DISCLOSURE NOTICE: The information contained in this release is as of August 13, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information that involves substantial risks and uncertainties about a potential initial public offering of a minority ownership stake in Pfizer’s Animal Health business. Such risks and uncertainties include, among other things, the possibility that the initial public offering will not be consummated within the anticipated time period or at all, including as the result of regulatory, market or other factors; risks relating to Pfizer Animal Health as a standalone business as the result of the variables and uncertainties inherent in business, financial and operating performance, including, among other things, competitive developments and general economic, political, business, industry, regulatory and market conditions; and the potential for disruption to Pfizer’s Animal Health business as the result of the initial public offering.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

All content set forth in this communication is subject to consultation with works councils, unions and employee representatives as required by and subject to local laws and regulations.

Global Markets Direct's, 'Seborrhea - Pipeline Review, H1 2012', provides an overview of the Seborrhea therapeutic pipeline. This report provides information on the therapeutic development for Seborrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seborrhea.

Scope

- A snapshot of the global therapeutic scenario for Seborrhea.

- A review of the Seborrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Seborrhea pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under development for Seborrhea.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Seborrhea therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/8cg3k7/seborrhea_pipeli

Source: Global Markets Direct

The UK express parcels market is approaching £7bn in size, having grown slowly in recent years in response to economic conditions. Parcel volumes suffered during the 2009 economic downturn and price pressure continued into 2010 with conditions only improving slightly in 2011-12.

The main drivers of parcel volumes are:

The growth of home shopping, which has been the main driver of growth in the consumer delivery sector right through the last decade, and depends on both customers' shopping habits and household penetration of enablers such as PCs and broadband access.

The overall level of economic activity, because parcels carriers serve such a wide variety of customers across so many different sectors of the economy: this stalled during 2008-09 and has faltered since.

Operator trends:

- There has been a trend for the operators with international networks and home delivery focus to increase their share of revenues at the expense of standalone UK B2B players such as UKMail and City Link.

- The sector continues to operate on narrow margins and, as an industry with significant fixed costs, is vulnerable to dips in volumes.

- Combined profitability across all the major operators fell from over 2% (EBIT) in 2006 to a net overall loss in 2008. It returned to profit in 2010 but available figures suggest another overall loss in 2011.

- Factors such as compatibility of operations with market segment focus appear to be far more important than the effects of scale in determining operator profitability.

Publication Overview

In this report Apex Insight reviews the UK parcels market encompassing both the business-to-business and business-to-consumer segments. The report quantifies the market size, historical growth rates, segmentation patterns and levels of industry profitability while reviewing key factors behind these figures. It also carries out an in-depth analysis of the relevant drivers of industry growth - in particular the macroeconomic environment and home shopping - setting out historical trends and available forecasts. The forecast for industry growth by segment is based in this analysis of historical trends and our understanding of growth drivers. While many reports on the industry contain data and description, a critical objective in writing this report has been to supplement this with insights and conclusions.

Who Should Buy This Report?

It is intended for parcels carriers themselves, users of their services, partners, investors, banks, analysts, consultants and other parties with interests in the sector.

Companies Mentioned

- APC

- City Link

- DHL

- DPD

- DX

- FedEx

- Hermes

- Interlink

- Nightfreight

- Parcelforce Worldwide

- Royal Mail

- TNT Express

- Tuffnells

- UK Mail

- UPS

- Yodel

For more information visit http://www.researchandmarkets.com/research/h674jn/uk_express_parcels

“Onchocerciasis (River Blindness) - Pipeline Review, H1 2012”

Scope

- A snapshot of the global therapeutic scenario for Onchocerciasis (River Blindness).
- A review of the Onchocerciasis (River Blindness) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Onchocerciasis (River Blindness) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under development for Onchocerciasis (River Blindness).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Onchocerciasis (River Blindness) pipeline depth and focus of Onchocerciasis (River Blindness) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


For more information visit http://www.researchandmarkets.com/research/r744sq/onchocerciasis_ri

Source: Global Markets Direct

„Wir möchten unsere Position international weiter ausbauen und sind in der Lage, durch den steten Auf- und Ausbau unseres Portfolios unseren Kurs des nachhaltigen Wachstums in der Games Branche weiterhin zu stärken“

Bis Jahresende will die Immanitas Entertainment GmbH mehr als 20 Titel veröffentlichen. „Wir möchten unsere Position international weiter ausbauen und sind in der Lage, durch den steten Auf- und Ausbau unseres Portfolios unseren Kurs des nachhaltigen Wachstums in der Games Branche weiterhin zu stärken“, betont Christian Sauerteig, Geschäftsführer der Immanitas Entertainment GmbH und ergänzt: „Die MyLoadBase N.V. bietet hierfür als Muttergesellschaft die idealen Rahmenbedingungen, um unsere Pläne umzusetzen.“

Über MyLoadBase N.V.:

Die MyLoadBase N.V. mit Sitz in Waalre entwickelt und vermarktet über ihre Töchter Qwazz Technologies GmbH, München, und Immanitas Entertainment GmbH, Velten, Online-Spiele auf Computern, Spielekonsolen und mobilen Geräten, wie Smartphones und Tablet-PC’s.

「スポーツには健康面での利点だけでなく、自信、自尊心、チーム・プレー、学校の成績の向上と、非常に多くの利点がありますので、すべての子供たちがスポーツのある人生を送ることが大切だと心から信じています。母親として、これは子供の時に始まるということを知っています。幸せなバランスのとれた子供を育成するのにスポーツが役立つように、遊びは赤ちゃんの発達に非常に大きな役割を持っています。世界中で母親や家族を支援する取り組みでP&Gとパンパースに協力できることをうれしく思います。」

P&G世界ブランド構築オフィサーのマーク・プリチャードは、次のように述べています。「『ありがとう、ママ』プログラムを開始する際に、各地の母親たちに母親を支援する良い方法とは何かということを質問すると、『若者のスポーツの支援に協力してください。スポーツは母親たちの力にもなります。スポーツは、母親が健康で幸せな子供を育てるのに役立ちますから』という答えが返ってきました。ですから、当社はオリンピック選手の母親だけでなく、子供の人生をできる限り最良のものにしようとあらゆる努力をするすべての母親を支援する取り組みをしています。」

プリチャードは、さらに次のように述べています。「パンパース、タイド、ジレット、パンテーンという当社のトップブランドにより、2012年に500万ドルを調達するという目標をすでに上回っています。600万ドル以上の資金によって世界各地のスポーツの発展、学校の機材、若者向けの基金・奨学金、夏季スポーツ・キャンプ施設を支援する予定です。本日の発表は、当社の10年にわたるIOCとのパートナーシップが終わるまで計画を延長し、世界各国の国内オリンピック委員会（NOC）と協力して多くの子供たちがスポーツやオリンピックの価値観を経験する機会を増やすことを意味します。」

IOCのジャック・ロゲ会長は、次のように述べています。「P&Gが世界的な若者向けスポーツ・プログラムを成功させているのは喜ばしいことです。2020年のオリンピック大会までこの取り組みが延長されることを歓迎します。世界的なオリンピック運動と提携することにより、P&Gはスポーツを通じて生活、特に若者の生活に影響を与え、向上をもたらすことに尽力してきました。若者のスポーツへの投資は、オリンピック運動の将来に不可欠です。」

米国のオリンピック選手で2012年ロンドン大会金メダリストのケリー・ウォルシュ選手は、P&Gが米国で若者向け基金を設立するのに貢献し、P&G最大のブランドであるパンパースと協力して赤ちゃんを遊びの精神で触発する支援を行いました。

ウォルシュ選手は、次のように述べています。「スポーツは、幼少期のころから私の人生を豊かで意義のあるものにする役割を果たしてきました。母親として、自分の子供たちが健康で豊かな生活を送れるよう後押しする上でスポーツが果たす役割は重要だと考えています。成長して将来のオリンピック選手になるかどうかにかかわらず、現在の小さなアスリートたちを支援することは非常に重要です。大切な生きる力を子供たちが身につける上でスポーツが役立つように、遊びは赤ちゃんの発達を促します。本日の発表に際してP&Gとパンパースに協力でき、うれしく思います。」

英国のオリンピック選手のポーラ・ラドクリフ選手は、P&Gがインスブルックで世界的な取り組みを発表するのに協力し、またパンパースのスポークスパーソンも務めています。ラドクリフ選手は、次のように述べています。「スポーツには健康面での利点だけでなく、自信、自尊心、チーム・プレー、学校の成績の向上と、非常に多くの利点がありますので、すべての子供たちがスポーツのある人生を送ることが大切だと心から信じています。母親として、これは子供の時に始まるということを知っています。幸せなバランスのとれた子供を育成するのにスポーツが役立つように、遊びは赤ちゃんの発達に非常に大きな役割を持っています。世界中で母親や家族を支援する取り組みでP&Gとパンパースに協力できることをうれしく思います。」

米国のオリンピック選手のタイソン・ゲイ選手は、ジレットの「始めよう（Get Started）」キャンペーンに参加しています。ゲイ選手は、次のように述べています。「生まれた時からスポーツの血が流れていました。子供の頃から、私の情熱は両親や祖母によって、また学校のトレーニング・プログラムを通じて育まれました。周囲のサポートによって、子供の頃に感じた刺激の種が大きくなり、現在のようなアスリートとなる力になりました。すべての子供たちが、人生の素晴らしいスタートを切るために同じサポートを受けられるべきだと思います。」

英国のオリンピック選手で銅メダリストのロビー・グラバーズ選手は、P&Gの発表に協力し、グラバーズ選手がよい人生のスタートを切るのを後押しする上で自分にとってのヒーローたちが果たした役割について語りました。グラバーズ選手は、次のように述べています。「若いアスリートへの支援は非常に重要です。ロジャー・ブラック選手、スティーブ・バックリー選手、ロン・ピカリング財団の支援がなければ、今ここにこうして銅メダルを持っていることはなかったという事実を考えると、子供たちがスポーツを経験できるようP&Gが支援するのに協力できるのは、光栄なことです。」

「若者のスポーツに投資することによって、当社は家族を支援し、将来のオリンピック選手育成に協力して、母親たちやIOCとの約束を守ることができます」と、マーク・プリチャードは語りました。

「ありがとう、ママ」キャンペーンは、すべてのメディアチャンネルと世界各国の小売店での店内プログラムで4月から展開されており、8月末まで続きます。オリンピック大会をテーマにしたP&Gブランド製品は、世界の400万を超える店舗で販売されています。

若者のスポーツへの取り組みに加えて、P&Gは2012年ロンドン大会後に有益で長期的な遺産を残すことを目的とした複数のプログラムの活動も開始しました。そのような活動として、P&Gブランドのアリエール、タイド、フラッシュ、ファブリーズはロンドンを「オリンピックにふさわしい」状態にするための英国首都清掃キャンペーンに取り組み、5000時間以上をかけて清掃活動を行い、1000袋以上のごみを集め、8000人のボランティアを「ロンドン大使」として募集・訓練しました。また、世界的なP&Gの活動として、オリンピック終了後にP&Gファミリー・ホームの設備をママや家族を支える地元の慈善団体に寄付することで「クリーンな足跡」を残す取り組みを行います。

写真や動画を含むP&G「ありがとう、ママ」キャンペーンに関連する資料と情報の全リストについては、www.PGThankYouMomMediaCenter.comをご覧ください。

# # #

編集者注記

P&Gについて

P&Gは当社のブランドを通じて世界中の約46億人に役立っています。信頼される高品質の当社トップブランドは世界でも最高レベルの充実度を誇るもので、パンパース、タイド、アリエール、オールウェイズ、ウィスパー、パンテーン、マッハ・スリー、バウンティ、ドーン、フェアリー、ゲイン、シャーミン、ダウニー、レノア、アイムス、クレスト、オーラルB、デュラセル、オーレイ、ヘッド＆ショルダーズ、ウエラ、ジレット、ブラウン、フュージョン、エース、ファブリーズ、アンビピュア、SK-II、ヴィックスなどがあります。P&Gは世界約75カ国で事業を展開しています。P&Gとそのブランドについての最新ニュースと詳細情報は、http://www.pg.comをご覧ください。

写真とマルチメディア・ギャラリーはこちらをご覧ください：http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50372126&lang=ja

本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。

“We are particularly encouraged by the 6-Minute Walk result, as this marks the first time that data on AMPYRA’s effects have been assessed on this measure.”

The study randomized 430 participants across three treatment arms: placebo, 5 mg or the currently marketed dose of 10 mg of dalfampridine-ER, twice daily. Baseline characteristics were measured at a single visit after randomization, following a qualifying screening visit. Study drug was then given for 4 weeks. Participants returned after 2 weeks on study drug for interim measurements (Visit 2), and again at 4 weeks (Visit 3).

The primary outcome was the change in walking speed (feet/second) on the Timed 25-Foot Walk (T25FW) test at Visit 3, measured at the time of peak plasma drug concentration, versus baseline.

Improvements in the primary outcome for the 5 mg dose (0.423 ft/sec, p=0.457) and the 10 mg dose (0.478 ft/sec, p=0.107) at Visit 3 were not statistically significant compared to placebo (0.363 ft/sec). The AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg registration studies used a consistent response analysis to allow for the variability in MS-related symptoms, including walking ability. The design of the current study required a single endpoint analysis that had not been used previously in the AMPYRA development program. In a post-hoc analysis, T25FW data were analyzed with methods similar to those used in the pivotal studies, combining all measures prior to treatment as the baseline and all measures on treatment as the on-drug value. The average change from baseline in walking speed was significantly greater for the 10 mg group compared to placebo (0.443 vs. 0.303 ft/sec, p=0.014) but not for the 5 mg group (0.366 vs. 0.303 ft/sec, p=0.292).

In addition, using a responder definition of average improvement in walking speed of at least 20% from baseline, similar to an analysis presented in the AMPYRA prescribing information, the 10 mg group showed significantly more responders than the placebo group (44% vs. 27%, p=0.004). The 5 mg group did not show a significant increase in response over placebo (32% vs. 27%, p=0.366).

A planned secondary outcome measure of improvement in walking, the 6-Minute Walk Test, was applied at Visit 2 in a subset of the study participants (approximately 50 randomized per treatment arm). The 10 mg dose, but not the 5 mg dose, showed a significant improvement compared to placebo (10 mg +129 ft vs. placebo +42 ft, p=0.014; 5 mg +77 ft vs. placebo +42 ft, p=0.308).

Changes in perceived effect of MS on walking-related activities, as measured by the self-reported 12-Item MS Walking Scale (MSWS-12), showed improvements for the 10 mg and 5 mg groups that were not significant compared to placebo (10 mg -11.1, p=0.286; 5 mg -9.7, p=0.866; placebo -8.4). A negative change represents reduced perceived disability.

“We believe the current study, together with the AMPYRA registration studies, continue to show that 10 mg twice daily is the appropriate, safe and effective dose. The 5mg twice daily dose of dalfampridine-ER failed to show efficacy over placebo on the primary or secondary measures. The 10 mg twice daily dose, which has consistently shown efficacy in our well-controlled clinical trials, did not meet the previously untested primary outcome measure selected for this study. We believe that this was due to increased patient variability, related to the study design. However, the 10 mg dose showed significant improvements in the 6-Minute Walk and in responder analyses of the Timed 25-Foot Walk,” said Enrique Carrazana, M.D., Acorda’s Chief Medical Officer. “We are particularly encouraged by the 6-Minute Walk result, as this marks the first time that data on AMPYRA’s effects have been assessed on this measure.”

No new safety signals were observed in this study. No seizures were reported. Two participants experienced serious adverse events in each of the 5 mg and the 10 mg treatment groups, including loss of consciousness in one patient in the 10 mg group who had discontinued dalfampridine-ER four days prior to the event. Adverse events that occurred in the combined dalfampridine-ER group at a rate of at least 2% greater than the placebo group included: urinary tract infection (8.0% vs. 5.6% placebo), nausea (7.7% vs. 3.5% placebo), dizziness (7.7% vs. 2.1% placebo), insomnia (6.3% vs. 4.2% placebo) and upper respiratory tract infection (2.8% vs. 0.7% placebo). Overall, adverse events were consistent with the U.S. Food and Drug Administration (FDA)-approved product labeling.

The study results will be provided to FDA and presented in peer-reviewed scientific forums. The Company is continuing to analyze data from the study.

AMPYRA is currently approved by the FDA as a treatment to improve walking ability in people with MS. This was demonstrated by an increase in walking speed. The only approved dosage strength of AMPYRA is 10 mg, which is taken twice daily. As specified in the product labeling, AMPYRA tablets should not be split, crushed, chewed or otherwise compromised, as doing will compromise the extended release properties of the tablet.

WEBCAST AND CONFERENCE CALL

Ron Cohen, President and Chief Executive Officer, Enrique Carrazana, Chief Medical Officer and Andrew Blight, Chief Scientific Officer, will host a conference call today at 8:30 a.m. ET to review the study results.

To participate in the conference call, please dial 866-730-5769 (domestic) or 857-350-1593 (international) and reference the access code 83883059. The presentation will be available via a live webcast on the Investor section of www.acorda.com.

A replay of the call will be available from 10:30 a.m. ET on August 13, 2012 until midnight on September 13, 2012. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 35919782. The archived webcast will be available for 30 days in the Investor Relations section of the Acorda website at www.acorda.com.

Important Safety Information

AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. The majority of seizures occurred at the recommended dose and in patients without a history of seizures, and generally within days to weeks of starting therapy. Discontinue AMPYRA use if seizure occurs.

AMPYRA is contraindicated in patients with moderate or severe renal impairment (CrCl less-than or equal to 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA and monitored at least annually during treatment with AMPYRA.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. Urinary tract infections were reported more frequently as adverse reactions in patients receiving AMPYRA 10 mg twice daily compared to placebo.

The most common adverse events (incidence greater-than or equal to 2% and at a rate greater than the placebo rate) for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.

For full U.S. Prescribing Information and Medication Guide for AMPYRA, please visit: www.AMPYRA.com.

About AMPYRA (dalfampridine)

AMPYRA is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), and is known as prolonged-, modified, or sustained-release fampridine (FAMPYRA^®) in some countries outside the United States (U.S.).

In laboratory studies, dalfampridine extended release tablets has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. AMPYRA is being developed and commercialized in the U.S. by Acorda Therapeutics; FAMPYRA is being developed and commercialized by Biogen Idec in markets outside the U.S. based on a licensing agreement with Acorda. AMPYRA and FAMPRYA are manufactured globally by Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, based on a supply agreement with Acorda.

AMPYRA is available by prescription in the United States. For more information about AMPYRA, including patient assistance and co-pay programs, healthcare professionals and people with MS can contact AMPYRA Patient Support Services at 888-881-1918.

AMPYRA Patient Support Services is available Monday through Friday, from 8:00 a.m. to 8:00 p.m. Eastern Time. For full U.S. Prescribing Information and Medication Guide, please visit: www.AMPYRA.com.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.

Acorda markets AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.

The Company also markets ZANAFLEX CAPSULES^® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES distributed by Watson Pharmaceutics, Inc. under its agreement with Acorda.

Acorda is developing an industry-leading pipeline of novel neurological therapies. The Company is studying AMPYRA to improve a range of functional impairments caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including any acquired or in-licensed programs; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

“Amer has contributed to our team for over a year now, and we’re proud to see his peer researchers acknowledge what we see every day at InVivo”

Dr. Khalil was awarded a grant of $10,000 for his project titled “Spinal cord repair using biomaterial-based drug-releasing strategies for reducing scarring and promoting regeneration.” Dr. Khalil’s project is important not only for InVivo’s second SCI product but also for the third product in the company’s portfolio, a platform intended for the reduction of fibrosis which has been developed to reduce scarring in both reparative surgical and dermatological applications. Combining the need for minimizing scarring after reparative surgery and the fast growing market demand for minimizing scarring following plastic surgery procedures, InVivo believes that this technology will result in millions of treatments per day in the U.S., and the company intends to lead the space.

“Amer has contributed to our team for over a year now, and we’re proud to see his peer researchers acknowledge what we see every day at InVivo,” said InVivo CEO Frank Reynolds. “Neurosurgeons have many career path options, and Amer’s commitment to helping move the ball forward in neurotrauma research makes him the perfect recipient for the MDHonors Research Award. This award clearly underscores the importance of InVivo’s spinal cord injury projects, and highlights Amer’s vital contributions to our efforts. This grant takes Amer one step further in his career as a surgeon-scientist and we’re delighted his contributions to our team are being recognized.”

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

About MDHonors

MDHonors is a division of LeadPhysician, an international physician organization based in London, which comprises more than 500,000 members. LeadPhysician is a leading online panel of practicing physicians who participate in medical research surveys for companies in the medical industry.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

“Amer has contributed to our team for over a year now, and we’re proud to see his peer researchers acknowledge what we see every day at InVivo”

Dr. Khalil was awarded a grant of $10,000 for his project titled “Spinal cord repair using biomaterial-based drug-releasing strategies for reducing scarring and promoting regeneration.” Dr. Khalil’s project is important not only for InVivo’s second SCI product but also for the third product in the company’s portfolio, a platform intended for the reduction of fibrosis which has been developed to reduce scarring in both reparative surgical and dermatological applications. Combining the need for minimizing scarring after reparative surgery and the fast growing market demand for minimizing scarring following plastic surgery procedures, InVivo believes that this technology will result in millions of treatments per day in the U.S., and the company intends to lead the space.

“Amer has contributed to our team for over a year now, and we’re proud to see his peer researchers acknowledge what we see every day at InVivo,” said InVivo CEO Frank Reynolds. “Neurosurgeons have many career path options, and Amer’s commitment to helping move the ball forward in neurotrauma research makes him the perfect recipient for the MDHonors Research Award. This award clearly underscores the importance of InVivo’s spinal cord injury projects, and highlights Amer’s vital contributions to our efforts. This grant takes Amer one step further in his career as a surgeon-scientist and we’re delighted his contributions to our team are being recognized.”

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

About MDHonors

MDHonors is a division of LeadPhysician, an international physician organization based in London, which comprises more than 500,000 members. LeadPhysician is a leading online panel of practicing physicians who participate in medical research surveys for companies in the medical industry.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.